Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386589 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05386589 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 14 participants.
The verdict
NCT05386589, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of N-hydroxycytidine (NHC) following a single oral dose of molnupiravir in participants 18 to 75 years (inclusive) with moderate hepatic impairment and healthy matched controls.
Interventions
- DRUG Molnupiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-06-14 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05386589
The ClinicalTrials.gov registry entry for NCT05386589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Molnupiravir is the first listed.
NCT05386589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05386589 about?
NCT05386589 is a clinical study titled "A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)". The purpose of this study is to evaluate the pharmacokinetics (PK) of N-hydroxycytidine (NHC) following a single oral dose of molnupiravir in participants 18 to 75 years (inclusive) with moderate hepatic impairment and healthy matched controls.
What is the current status of trial NCT05386589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-06-14. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT05386589?
The interventions under investigation include: Molnupiravir (DRUG).
Who is sponsoring clinical trial NCT05386589?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.